

## PRIOR AUTHORIZATION POLICY

**POLICY:** Ophthalmology – Dry Eye Disease – Miebo Prior Authorization Policy

- Miebo™ (perfluorohexyloctane ophthalmic solution – Bausch & Lomb)

**REVIEW DATE:** 04/10/2024

---

### OVERVIEW

Miebo, a semifluorinated alkane, is indicated for the treatment of the signs and symptoms of **dry eye disease** (DED).<sup>1</sup> The safety and effectiveness of Miebo in pediatric patients < 18 years of age have not been established.

### Guidelines

The American Academy of Ophthalmology (AAO) Dry Eye Syndrome Preferred Practice Pattern® (2024) notes dry eye syndrome is also known as dry eye disease or keratoconjunctivitis sicca.<sup>2</sup> Dry eye is generally classified according to both symptoms and signs (i.e., mild, moderate, or severe); however, there is an emphasis on symptoms over signs. Management of dry eye is listed as a four-step staged approach, but specific therapies may be chosen from any step, regardless of the level of disease severity, depending on provider experience and patient preference. Miebo, as well as other FDA-approved therapies for dry eye disease (cyclosporine ophthalmic products, Tyrvaya® [varenicline nasal spray], and Xiidra® [lifitegrast ophthalmic solution]), are noted as Step 2 options in the Preferred Practice Pattern. The AAO notes use of any of these FDA-approved products may lead to improvement of patient symptoms and/or signs but none has been proven more effective than the other in head-to-head trials; there are no direct comparisons in a prospective clinical trial in the literature.

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Miebo. All approvals are provided for the duration noted below.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Miebo is recommended in those who meet the following criteria:

#### FDA-Approved Indication

1. **Dry Eye Disease.** Approve for 1 year if the patient is  $\geq 18$  years of age.  
Note: Examples of dry eye disease include dry eye syndrome and keratoconjunctivitis sicca.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Miebo is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. Miebo™ ophthalmic solution [prescribing information]. Bridgewater, NJ: Bausch & Lomb; May 2023.

04/10/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

2. Amescua G, Ahmad S, Cheung AY, et al. American Academy of Ophthalmology Preferred Practice Pattern Cornea and External Disease Panel. Dry Eye Syndrome Preferred Practice Pattern®. *Ophthalmology*. 2024;131(4);P1-P49.